Page 231 - Binder2
P. 231
centers, specialty pharmacies, refrigeration, and insurance
gating.
In this way, edible antibody therapies don’t just extend the
reach of biologics.
They redefine what it means to deploy them.
What’s Next
Multiple groups are now advancing oral antibody programs
toward the clinic, including therapies for IBD, enteric
infections, and food allergy. Early data has shown that:
• Plant-produced IgA remains stable in simulated
digestion
• Oral delivery achieves therapeutic levels in the gut
• Mucosal binding specificity can be preserved across
platforms
If these results hold, the implications are enormous. Oral
antibodies could become first-line biologics for mucosal
disease—cheaper to make, easier to take, and less likely to
fail due to immune rejection.
Once again, we see the power of edible biologics not just to
improve delivery, but to shift the entire design
philosophy of a drug.
The future of antibodies isn’t just more humanized.
It’s more localized, more accessible, and more edible.
229
